Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).
Anna F. Farago(Massachusetts General Hospital), Alice T. Shaw(Dana-Farber Cancer Institute), Judith Marcoux(Beth Israel Deaconess Medical Center), Daniel A. Haber(Howard Hughes Medical Institute), Allison Charles(Massachusetts General Hospital), Christopher G. Azzoli(Massachusetts General Hospital), Nicholas J. Dyson(Massachusetts General Hospital), David A. Barbie(Dana-Farber Cancer Institute), Rebecca S. Heist(Massachusetts General Hospital), Shyamala Maheswaran(Massachusetts General Hospital), Mari Mino–Kenudson(Massachusetts General Hospital), Lecia V. Sequist(Harvard University), Benjamin J. Drapkin(Southwestern Medical Center), Jun Zhong(Massachusetts General Hospital), Aaron N. Hata(Harvard University), David T. Myers(Harvard University), David M. Jackman(Brigham and Women's Hospital), Sarah Phat(Harvard University), Beow Y. Yeap(Harvard University), Jane Bailey Grinnell(Massachusetts General Hospital)
Cited by 8
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k